| AH 7614FFA4/GPR120 antagonist |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 98.75%
- COA (Certificate Of Analysis)
- HPLC
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
| Cell experiment [1]: | |
Cell lines | Flp-In T-REx 293 cells |
Preparation method | The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | 10-10 ~10-5 M for 15 minutes |
Applications | AH-7614 inhibited, in a potent and concentration-dependent manner, the ability of ω-3 fatty acid aLA to promote Ca2+ mobilization in Flp-In T-REx 293 cells induced to express hFFA4-eYFP. As an antagonist of FFA4, AH-7614 is able to block effects of both the polyunsaturated ω-6 fatty acid linoleic acid |
References: [1] Watterson KR, Hansen SVF, Hudson BD, et al. Probe-Dependent Negative Allosteric Modulators of the Long-Chain Free Fatty Acid Receptor FFA4. Mol Pharmacol. 2017 Jun;91(6):630-641. | |
AH 7614 Dilution Calculator
calculate
AH 7614 Molarity Calculator
calculate
| Cas No. | 6326-06-3 | SDF | Download SDF |
| Synonyms | N/A | ||
| Chemical Name | 4-methyl-N-(9H-xanthen-9-yl)benzenesulfonamide | ||
| Canonical SMILES | O=S(NC1C2=C(C=CC=C2)OC3=CC=CC=C31)(C4=CC=C(C)C=C4)=O | ||
| Formula | C20H17NO3S | M.Wt | 351.42 |
| Solubility | ≥35.1mg/mL in DMSO | Storage | Store at -20°C |
| Physical Appearance | A crystalline solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
Target: FFA4/GPR120
IC50: N/A
AH7614 is a selective and potent free fatty acid receptor 4 (FFA4/GPR120) antagonist with pIC50 values of 7.1, 8.1 and 8.1 at the human, mouse and rat receptor, respectively [1]. The free fatty acid receptor 4 (FFA4/GPR120), a member of the G protein-coupled receptor family, is a potential 7TM receptor involved in long-chain fatty acid-stimulated glucagon-like peptide-1 (GLP-1) secretion. FFA4 is highly expressed in the intestinal endocrine cell line STC-1 and the intestine. GLP-1 regulates multiple physiological functions including eating behavior [2].
In vitro: AH7614 (0.063, 0.25, and 1μM) blocked linoleic acid and GSK137647A-induced intracellular calcium increase in U2OS osteosarcoma cells expressing the FFA4 receptor [1]. In addition, the increase of glucose-stimulated insulin secretion by GSK137647A (50 μM) was abolished in the presence of the selective FFA4 antagonist AH7614 (100 μM) in the MIN6 mouse insulinoma cell line. Moreover, AH7614 (100 μM) blocked GSK137647A (100μM)-mediated a modest increase of GLP-1 secretion in the NCIH716 cells [1].
In vivo: N/A
References:1. Sparks SM, Chen G, Collins JL, Danger D, Dock ST, Jayawickreme C, et al. Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120). Bioorg Med Chem Lett. 2014;24(14):3100-3. 2. Martin C, Passilly-Degrace P, Chevrot M, Ancel D, Sparks SM, Drucker DJ, et al. Lipid-mediated release of GLP-1 by mouse taste buds from circumvallate papillae: putative involvement of GPR120 and impact on taste sensitivity. J Lipid Res. 2012;53(11):2256-65.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
1.若都为正常，那么并未有太大问题，只要定期复查就可以了。
2.如果TGAb、TMAb、甲状腺功能均高，那么就是桥本氏甲状腺炎并甲亢，需要抗甲亢治疗。
3.如果TGAb、TMAb高，甲状腺功能下降，那么就是桥本氏甲状腺炎并甲减，需要进行甲减治疗。
4.如果TGAb、TMAb高，甲状腺功能正常，那么就是桥本氏甲状腺炎，无需特殊治疗，只要定期复查甲状腺功能就可能以了，不过这种情况有可能以后演变成甲减或者甲亢。
BAS-ELISA是在常规ELISA原理的基础上，结合生物素(B)与亲和素(A)间的高度放大作用，而建立的一种检测系统。生物素很易与蛋白质(如抗体等)以共价键结合。这样，结合了酶的亲和素分子与结合有特异性抗体的生物素分子产生反应，既起到了多级放大作用，又由于酶在遇到相应底物时的催化作用而呈色，达到检测未知抗原(或抗体)分子的目的。
1.若都为正常，那么并未有太大问题，只要定期复查就可以了。
2.如果TGAb、TMAb、甲状腺功能均高，那么就是桥本氏甲状腺炎并甲亢，需要抗甲亢治疗。
3.如果TGAb、TMAb高，甲状腺功能下降，那么就是桥本氏甲状腺炎并甲减，需要进行甲减治疗。
4.如果TGAb、TMAb高，甲状腺功能正常，那么就是桥本氏甲状腺炎，无需特殊治疗，只要定期复查甲状腺功能就可能以了，不过这种情况有可能以后演变成甲减或者甲亢。
试题分析：酶是一种生物催化剂，在催化反应中本身不发生变化；此非酶的特性；B项体现了酶的作用条件较温和的特性；C项体现了酶的专一性；D项体现了酶的高效性；故选A。
考点：本题考查的是酶的特性。
点评：对于此类试题，学生应掌握酶的特性。
